Amicus Therapeutics, Inc (FOLD) Debt by Year
Amicus Therapeutics, Inc carried $392.7M in long-term debt against $214.0M in cash and equivalents at the end of fiscal year 2025. This represents an increase of 0.7% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Amicus Therapeutics, Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
FOLD Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $392.7M+0.7% | $390.1M+0.6% | $387.9M-1.1% | $392.0M+0.7% | $389.4M0.0% | $389.3M+160.4% | $149.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $214.0M+0.1% | $213.8M-13.5% | $247.0M+66.0% | $148.8M-39.3% | $245.2M+50.2% | $163.2M+14.3% | $142.8M+79.1% | $79.7M+62.6% | $49.1M-73.8% | $187.0M+169.2% | $69.5M+188.6% | $24.1M-44.8% | $43.6M+28.5% | $34.0M+32.3% | $25.7M |
FOLD Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $392.7M+0.7% | $392.0M+0.6% | $391.3M+0.6% | $390.7M+0.6% | $390.1M+0.6% | $389.5M-1.2% | $388.9M-1.1% | $388.4M-1.1% | $387.9M-1.1% | $394.1M+0.7% | $393.4M+0.7% | $392.7M+0.7% |
| Cash & Equivalents | $214.0M+0.1% | $190.6M-18.4% | $158.7M-24.2% | $181.7M-13.4% | $213.8M-13.5% | $233.6M-11.3% | $209.3M-0.9% | $209.8M+30.6% | $247.0M+66.0% | $263.3M-5.1% | $211.3M-10.3% | $160.6M-31.2% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Amicus Therapeutics, Inc financials
Frequently Asked Questions
What was Amicus Therapeutics, Inc's long-term debt in fiscal year 2025?
Amicus Therapeutics, Inc carried $392.7M in long-term debt against $214.0M in cash and equivalents at the end of fiscal year 2025.
How fast is Amicus Therapeutics, Inc's long-term debt growing?
Amicus Therapeutics, Inc (FOLD) long-term debt rose by 0.7% year over year, from $390.1M to $392.7M in fiscal year 2025.
What was Amicus Therapeutics, Inc's long-term debt in the most recent quarter?
Amicus Therapeutics, Inc (FOLD) reported $392.7M in long-term debt in Q4 2025. This represents an increase of 0.7% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Amicus Therapeutics, Inc (FOLD) reported on that line in every period on record.